Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2025

Conditions
Breast Cancer Stage 2 and 3
Interventions
DRUG

Fenofibrate

It is an approved drug for hypercholesterolemia, It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα).

OTHER

Placebo

Placebo is made to look exactly like a real drug but is made of an inactive substance.

DRUG

Doxorubicin

Anthracycline derived chemotherapy used in treatment of breast cancer

DRUG

Cyclophosphamide

Alkylating agent used in treatment of breast cancer

Trial Locations (1)

31527

Hagar Dewidar, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT06155331 - Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients | Biotech Hunter | Biotech Hunter